EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study

Raffaella Viganò, Alessandro Loglio, Clara Dibenedetto, Paola Carrai, Silvia Martini, Ilaria Lenci, Bianca Magro, Sara Conti, Paolo Angelo Cortesi iD, Chiara Mazzarelli, Chiara Becchetti, Giovanni Perricone iD und 13 weitere

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70348 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Raffaella Viganò und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology and Gastroenterology Unit, ASST GOM Niguarda, Milan, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Immunoglobulins, Liver Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Despite recommendations from scientific societies that hepatitis B immunoglobulin (HBIG) can be safely discontinued, centres across Europe continue to use the combination nucleoside analogues (NAs) plus HBIG for long‐term prophylaxis against hepatitis B virus (HBV) recurrence after liver transplant (LT). The aim of this study was to evaluate the safety of HBIG withdrawal in a cohort of LT recipients on long‐term HBIG+NAs.

Methods

All patients under third‐generation NAs + HBIG and who adhered to the INSIGHT‐B protocol were followed up after HBIG withdrawal, in a multicentre, prospective, Italian cohort study, to evaluate the risk of HBV reactivation. The probability of HBsAg reappearance after HBIG withdrawal, stratified by presence of HCC at LT, was estimated through Kaplan–Meier curves and Log‐rank tests.

Results

Between February 2021 and January 2024, 222 liver transplant (LT) recipients withdrew HBIG 11.6 (IQR 6.7–17.0) years after LT and were followed up for a median time of 24 months. After HBIG withdrawal, Hepatitis B surface antigen (HBsAg) reappearance was observed in 12 patients (5.4%) with a cumulative 1‐, 2‐ and 3‐year recurrence rate of 4.08%, 5.36% and 6.89% respectively. HBsAg serum levels remained very low over the entire period of observation (median 9 months, range 3–20), and in four cases fluctuated around the detectability threshold. In all cases, HBV‐DNA persisted undetectable, liver function tests (LFTs) remained within the normal range, and neither HBV‐related hepatitis nor HCC were observed. No baseline patients' features were found to be significantly associated with the likelihood of HBsAg reappearance after HBIG withdrawal, including the presence of HCC at transplantation.

Conclusions

HBIG could be safely withdrawn in HBV mono‐infected LT recipients on long‐term combination HBIG plus third generation NAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis BImmunoglobulinsLiver TransplantationAdultAgedFemaleHumansMaleMiddle AgedHepatitis B Surface AntigensHepatitis B virusItalyProspective Studies

Stichwörter der Autor:innen

HBV‐DNAentecavirhepatitis B immunoglobulinshepatocellular carcinomaliver transplantationrecurrent hepatitis Btenofovir alafanamide fumaratotenofovir disoproxil fumarato

Substanzen

Antiviral Agentshepatitis B hyperimmune globulinHepatitis B Surface AntigensImmunoglobulins

Autor:innen und Institutionen

  • Hepatology and Gastroenterology Unit, ASST GOM Niguarda, Milan, Italy.
  • Gastroenterology, Hepatology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Gastroenterology and Hepatology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Hepatobiliary Surgery and Liver Transplantation Unit, University of Pisa Medical School and Hospital, Pisa, Italy.
  • SSD Insufficienza Epatica e Trapianto Epatico, AOU Città Della Salute e della Scienza di Torino, Turin, Italy.
  • Hepatology Unit, Tor Vergata University, Rome, Italy.

ORCID-Profile: Paolo Angelo Cortesi, Giovanni Perricone, Elisabetta Degasperi, Pietro Lampertico, Stefano Fagiuoli

Zitieren

APA

Viganò, R., Loglio, A., Dibenedetto, C., Carrai, P., Martini, S., Lenci, I., Magro, B., Conti, S., Cortesi, P. A., Mazzarelli, C., Becchetti, C., Perricone, G., Cucco, M., Carbone, M., Cocchis, D., Farina, E., Pasulo, L., Viganò, M., Sagasta, M., …, & INSIGHT‐B study group (2026). Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70348

Vancouver

Viganò R, Loglio A, Dibenedetto C, Carrai P, Martini S, Lenci I, et al. Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70348

BibTeX
@article{Vigan2026,
  author = {Viganò, Raffaella and Loglio, Alessandro and Dibenedetto, Clara and Carrai, Paola and Martini, Silvia and Lenci, Ilaria and Magro, Bianca and Conti, Sara and Cortesi, Paolo Angelo and Mazzarelli, Chiara and Becchetti, Chiara and Perricone, Giovanni and Cucco, Monica and Carbone, Marco and Cocchis, Donatella and Farina, Elisa and Pasulo, Luisa and Viganò, Mauro and Sagasta, Michele and Degasperi, Elisabetta and Ghinolfi, Davide and Lampertico, Pietro and Fagiuoli, Stefano and Belli, Luca Saverio and INSIGHT‐B study group, INSIGHT‐B study group},
  title = {Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70348}
}
Kostenlos starten →